Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) FCF Margin (2016 - 2025)

Historic FCF Margin for Neurocrine Biosciences (NBIX) over the last 14 years, with Q4 2025 value amounting to 48.52%.

  • Neurocrine Biosciences' FCF Margin rose 110500.0% to 48.52% in Q4 2025 from the same period last year, while for Dec 2025 it was 26.17%, marking a year-over-year increase of 25200.0%. This contributed to the annual value of 26.17% for FY2025, which is 25200.0% up from last year.
  • Neurocrine Biosciences' FCF Margin amounted to 48.52% in Q4 2025, which was up 110500.0% from 26.96% recorded in Q3 2025.
  • Neurocrine Biosciences' FCF Margin's 5-year high stood at 48.52% during Q4 2025, with a 5-year trough of 31.8% in Q1 2023.
  • Moreover, its 4-year median value for FCF Margin was 24.1% (2024), whereas its average is 22.84%.
  • Over the last 5 years, Neurocrine Biosciences' FCF Margin had its largest YoY gain of 549200bps in 2024, and its largest YoY loss of -291900bps in 2024.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' FCF Margin stood at 35.0% in 2021, then plummeted by -34bps to 22.92% in 2023, then soared by 63bps to 37.47% in 2024, then increased by 29bps to 48.52% in 2025.
  • Its last three reported values are 48.52% in Q4 2025, 26.96% for Q3 2025, and 13.02% during Q2 2025.